Ventricular system

$1.3 Billion Worldwide Intracranial Pressure (ICP) Monitoring Devices Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Infectious diseases, Health, Medical devices, Branches of biology, Neurotrauma, Medical signs, Intracranial pressure, Neurophysiology, Ventricular system, ICP

The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Intracranial Pressure (ICP) Monitoring Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
  • Invasive, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$1.7 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $365 Million, While China is Forecast to Grow at 8.1% CAGR
    The Intracranial Pressure (ICP) Monitoring Devices market in the U.S. is estimated at US$365 Million in the year 2020.

Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Syndromes, Health, Clinical medicine, Rare diseases, Ventricular system, Sanfilippo syndrome, Hunter syndrome, Cerebrospinal fluid, Mucopolysaccharidosis

The new data was presented during an oral presentation at the 16th International Symposium on MPS and Related Diseases.

Key Points: 
  • The new data was presented during an oral presentation at the 16th International Symposium on MPS and Related Diseases.
  • Brain volume loss is characteristic in children with MPS IIIA and is associated with long-term cognitive and physical disability.
  • Secondary endpoints include brain volume, behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma and urine, and liver volume.
  • The Transpher A Study (NCT02716246) is an ongoing, two-year, open-label, dose-escalation, Phase 1/2 global clinical trial assessing ABO-102 for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA).

Anuncia, Inc. Selects Scottsdale, Ariz. for New HQ to Further Develop Lifesaving Medtech

Retrieved on: 
Wednesday, June 30, 2021
Medicine, Ventricular system, Medical equipment, Neurosurgical procedures, Cerebral shunt, Shunt, Zimmer Biomet Robotics, Branches of biology

The move is the first geographic expansion for the high growth medtech startup previously based in Massachusetts.

Key Points: 
  • The move is the first geographic expansion for the high growth medtech startup previously based in Massachusetts.
  • Anuncia is the developer of the US FDA cleared and EU CE Marked commercial ReFlow Ventricular System designed to noninvasively unblock occluded ventriculoperitoneal (VP) shunts.
  • As many as half of all intracranial VP shunts fail in the first two years, mainly due to blockages that impair CSF flow.
  • The warm welcome and support has been unparalleled and makes us feel Arizona is truly invested in our future.

Anuncia ReFlow™ Tech Honored With Fast Company 2021 World Changing Ideas Awards

Retrieved on: 
Tuesday, May 4, 2021
Ventricular system, Reflow soldering, Soldering, Cerebrospinal fluid, Shunt, CSF, Medicine

b'LOWELL, Mass., May 4, 2021 /PRNewswire/ -- Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company\'s 2021 World Changing Ideas Awards for its ReFlow medical device platform.

Key Points: 
  • b'LOWELL, Mass., May 4, 2021 /PRNewswire/ -- Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company\'s 2021 World Changing Ideas Awards for its ReFlow medical device platform.
  • A panel of eminent Fast Company editors and reporters selected honorees from a pool of more than 4,000 entries across categories and the globe.
  • The ReFlow System Mini and ReFlow Smart Shunt features are under development and not available for sale.
  • For more information, please visit www.anunciainc.com .\nAbout the World Changing Ideas Awards: World Changing Ideas is one of Fast Company\'s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better.

Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

Retrieved on: 
Wednesday, April 7, 2021
Oncology, Health, General Health, Clinical trials, Research, Science, Biotechnology, Branches of biology, Neurology, Ventricular system, Biology, Natural sciences, Cerebrospinal fluid, Neuro-Oncology, Assay

Amir Azadi, MD is a medical oncologist specializing in neuro-oncology and an Assistant Professor in the Department of Neurology at Barrow Neurological Institute.

Key Points: 
  • Amir Azadi, MD is a medical oncologist specializing in neuro-oncology and an Assistant Professor in the Department of Neurology at Barrow Neurological Institute.
  • Dr. Azadi received his medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran.
  • In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing its cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system.
  • The Companys CSF assay identifies molecular targets for clinical decision making and provides quantitative information for monitoring treatment response.

Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Health, Genetics, Clinical trials, Oncology, Medicine, Clinical medicine, Branches of biology, Ventricular system, Neurology, Assay, Biochemistry, Titration, Liquid biopsy, Biopsy, Cerebrospinal fluid

Nicholas Blondin, MD is Assistant Professor of Clinical Neurology at Yale School of Medicine.

Key Points: 
  • Nicholas Blondin, MD is Assistant Professor of Clinical Neurology at Yale School of Medicine.
  • Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.
  • In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing its cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system.
  • The Companys CSF assay identifies molecular targets for clinical decision making and provides quantitative information for monitoring treatment response.

Anuncia Inc. Receives FDA "Breakthrough Device Designation" for ReFlow™ System Mini

Retrieved on: 
Tuesday, March 2, 2021
Healthcare reform in the United States, Federal assistance in the United States, Presidency of Lyndon B. Johnson, Ventricular system, Health, Branches of biology, Child poverty, Medicaid, Medicare, Reflow soldering, Hydrocephalus, Normal pressure hydrocephalus

Elsa Abruzzo, President of Anuncia Inc., stated, "Our team is very pleased to achieve this significant milestone making the ReFlow System Mini eligible for prioritized FDA regulatory review and Centers for Medicare and Medicaid (CMS) Medicare Coverage of Innovation Technology (MCIT) reimbursement review."

Key Points: 
  • Elsa Abruzzo, President of Anuncia Inc., stated, "Our team is very pleased to achieve this significant milestone making the ReFlow System Mini eligible for prioritized FDA regulatory review and Centers for Medicare and Medicaid (CMS) Medicare Coverage of Innovation Technology (MCIT) reimbursement review."
  • "The ReFlow System Mini is optimized to serve a broad hydrocephalus populationinfants with non-communicating hydrocephalus, young women with pseudotumor cerebri, and older patients with communicating, idiopathic normal pressure hydrocephalus (iNPH).
  • The ReFlow System Mini is under development and not available for sale.
  • The ReFlow System is a prescription device sold by or on the order of a physician.

West-Atlantic Partners Closes Acquisition of PrecisionMed, Inc.

Retrieved on: 
Wednesday, January 13, 2021
Branches of biology, Body fluids, Neurology, Domesticated plants, Cerebrospinal fluid, Ventricular system, Flax

SOLANA BEACH, Calif., Jan. 13, 2021 /PRNewswire/ --West-Atlantic Partners ("West-Atlantic") announced today that it has acquired PrecisionMed, Inc. ("PrecisionMed") from its founders, John Flax, MD and Ronald Flax.

Key Points: 
  • SOLANA BEACH, Calif., Jan. 13, 2021 /PRNewswire/ --West-Atlantic Partners ("West-Atlantic") announced today that it has acquired PrecisionMed, Inc. ("PrecisionMed") from its founders, John Flax, MD and Ronald Flax.
  • PrecisionMed is the premier provider of human cerebrospinal fluid (CSF) for scientific research, and has the largest private collection of CSF for research in the world.
  • John Flax, MD, CEO of PrecisionMed, said, "We are excited to partner with West-Atlantic to set the stage for the company's next phase of growth.
  • EVOLUTION Life Science Partners acted as financial advisor to PrecisionMed and Solomon Ward Seidenwurm & Smith, LLP acted as legal advisor.

Global Cerebrospinal Fluid (CSF) Management Market 2020-2025 by Shunt Type, Shunt Valve Type, Patient Population - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 19, 2020
Medical devices, Health, Branches of biology, Anatomy, Ventricular system, Body fluids, Medical specialties, Cerebrospinal fluid, Neurology, Shunt, Medical equipment, ShuntCheck, Lumbar–peritoneal shunt

The "Global Cerebrospinal Fluid (CSF) Management Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cerebrospinal Fluid (CSF) Management Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global cerebrospinal fluid (CSF) management market is estimated to grow at a CAGR of 4.27% from a market value of USD748.406 million in 2019 to achieve a market value of USD961.819 million by the end of 2025.
  • Cerebrospinal fluid (CSF) management makes use of devices like shunts and drainage systems for the maintenance of the CSF flow and provides assistance in draining excess CSF fluid from brain.
  • Geographically, North America is estimated to hold a significant market share in the global cerebrospinal fluid management market.

Hydrocephalus Shunts Market to Reach $322.01 Mn, Globally, by 2027 at 2.8% CAGR: Allied Market Research

Retrieved on: 
Monday, November 9, 2020
Ventricular system, Branches of biology, Paradoxidoidea, Medical specialties, Clinical medicine, Hydrocephalus, Pediatrics, Shunt, Medical equipment, Cerebral shunt

According to the report, the global hydrocephalus shunts market generated $291.00 million in 2019, and is expected to garner $322.01 million by 2027, growing at a CAGR of 2.8% from 2020 to 2027.

Key Points: 
  • According to the report, the global hydrocephalus shunts market generated $291.00 million in 2019, and is expected to garner $322.01 million by 2027, growing at a CAGR of 2.8% from 2020 to 2027.
  • Rise in prevalence of hydrocephalus, growth in adoption of advanced programmable valves, and surge in incidences of neurological disorder drive the growth of the global hydrocephalus shunts market.
  • However, shunt malfunction and related infections and shunt-free treatments for hydrocephalus restrain the market growth.
  • The global hydrocephalus shunts market across North America, contributed to the highest share in terms of revenue, holding more than two-fifths of the total market share in 2019.